

ID807: Ixazomib for multiple myeloma: Addendum due to lenalidomide PAS

The PASLU has confirmed that the lenalidomide PAS where the lenalidomide company funds lenalidomide drug use after two years does not apply to the 1 prior subgroup. The 1 prior cost effectiveness estimates of the ERG need to be amended. This affects the ERG analyses 1, 3 and 4. Due to time pressures the ERG has only amended the cost effectiveness estimates inclusive of the ixazomib PAS.

Base case analyses

ERG Analysis 1: 1 prior and company NMA: IXA+LEN+DEX vs BORT+DEX

Table 01: ERG revised company base case: 1 prior subgroup: Inc PAS

	Undisc. LY			QALYs			Costs			
	PFS	PPS	OS	PFS	PPS	Total	Drug	ConMed	Ongoing	Total
BORD	1.920	0.953	2.873	1.259	0.553	1.779	£27,007	£9,520	£5,504	£44,707
IXAL	2.168	5.007	7.175	1.415	2.547	3.932	£199,616	£21,145	£14,756	£238,733
Net	0.249	4.054	4.302	0.155	1.994	2.153	£172,609	£11,626	£9,252	£194,026
ICER										£90,117

ERG Analysis 3: 1 prior: IXA+LEN+DEX vs LEN+DEX and company TMM-1 curves

Table 02: ERG revised base case: 1 prior subgroup: versus LEN+DEX: Inc PAS

	Undisc. LY			QALYs			Costs			
	PFS	PPS	OS	PFS	PPS	Total	Drug	ConMed	Ongoing	Total
LEND	2.033	6.000	8.033	1.330	3.025	4.326	£108,117	£23,319	£16,890	£151,450
IXAL	2.168	5.007	7.175	1.415	2.547	3.932	£199,616	£21,145	£14,756	£238,733
Net	0.135	-0.993	-0.858	0.085	-0.478	-0.394	£91,499	-£2,173	-£2,133	£87,283
ICER										Dom'ted

ERG Analysis 4: 1 prior and ERG NMA: IXA+LEN+DEX vs BORT+DEX: Inc PAS

Table 03: ERG revised base case: 1 prior subgroup: ERG NMA: Inc PAS

	Undisc. LY			QALYs			Costs			
	PFS	PPS	OS	PFS	PPS	Total	Drug	ConMed	Ongoing	Total
BORD	2.073	6.027	8.099	1.352	3.032	4.356	£27,181	£23,480	£16,865	£69,872
IXAL	2.168	5.007	7.175	1.415	2.547	3.932	£199,616	£21,145	£14,756	£238,733
Net	0.096	-1.020	-0.924	0.062	-0.485	-0.424	£172,436	-£2,335	-£2,109	£168,861
ICER										Dom'ted

Sensitivity analyses

Table 04: SA01: OS Curves: PAS inclusive

Analysis	ERG 1	ERG 3	ERG 4
Subgroup	1 prior	1 prior	1 prior
Comparator	BORT+DEX	LEN+DEX	BORT+DEX
NMA	Comp 1+ prior	n.a.	ERG 1+ prior
Curves	Comp 1 prior	Comp 1 prior	Comp 1 prior
Base case.	£90,117	Dom'ted	Dom'ted
Exponential	£84,111	Dom'ted	Dom'ted
Weibull	£122k	Dom'ted	Dom'ted
Log Normal	£69,846	Dom'ted	Dom'ted
Log Logistic	£81,064	Dom'ted	Dom'ted
Gompertz	£195k	Dom'ted	Dom'ted
Gamma	£75,018	Dom'ted	Dom'ted

Table 05: SA02: PFS Curves: PAS inclusive

Analysis	ERG 1	ERG 3	ERG 4
Subgroup	1 prior	1 prior	1 prior
Comparator	BORT+DEX	LEN+DEX	BORT+DEX
NMA	Comp 1+ prior	n.a.	ERG 1+ prior
Curves	Comp 1 prior	Comp 1 prior	Comp 1 prior
Base case.	£90,117	Dom'ted	Dom'ted
Exponential	£89,908	Dom'ted	Dom'ted
Weibull	£90,217	Dom'ted	Dom'ted
Log Normal	£89,283	Dom'ted	Dom'ted
Log Logistic	£89,451	Dom'ted	Dom'ted
Gompertz	£90,509	Dom'ted	Dom'ted
Gamma	£90,117	Dom'ted	Dom'ted

Table 06: SA03: ToT Curves: PAS inclusive

Analysis	ERG 1	ERG 3	ERG 4
Subgroup	1 prior	1 prior	1 prior
Comparator	BORT+DEX	LEN+DEX	BORT+DEX
NMA	Comp 1+ prior	n.a.	ERG 1+ prior
Curves	Comp 1 prior	Comp 1 prior	Comp 1 prior
Base case.	£90,117	Dom'ted	Dom'ted
Exponential	£103k	Dom'ted	Dom'ted
Weibull	£90,117	Dom'ted	Dom'ted
Log Normal	£148k	Dom'ted	Dom'ted
Log Logistic	£132k	Dom'ted	Dom'ted
Gompertz	£81,164	Dom'ted	Dom'ted
Gamma	£88,917	Dom'ted	Dom'ted

Table 07: Sensitivity analyses SA04 to SA09: PAS inclusive

Analysis	ERG 1	ERG 3	ERG 4
Subgroup	1 prior	1 prior	1 prior
Comparator	BORT+DEX	LEN+DEX	BORT+DEX
NMA	Comp 1+ prior	n.a.	ERG 1+ prior
Curves	Comp 1 prior	Comp 1 prior	Comp 1 prior
Base case.	£90,117	Dom'ted	Dom'ted
SA04: ERG 1 prior	Dom'ted
SA05: IXAL HRs	£71,068	£354k	£751k
SA06a: TA171 Qol	£91,103	Dom'ted	Dom'ted
SA06b: TA338 Qol	£96,246	Dom'ted	Dom'ted
SA07: BORT 5wk	£90,706	..	Dom'ted
SA08: no ToT, PFS	£107k	Dom'ted	Dom'ted
SA09: PPS costs	£135k	Dom'ted	Dom'ted

Additional scenario analyses

ERG OS NMA result

NICE has also requested that the ERG provide an estimate using the original company model corrected for the 5 month delay not being applied to the delayed exponential for BOR+DEX, removing the lenalidomide PAS from the calculations and applying the ERG NMA OS HR estimate. The sequential, cumulative effect of making these changes is outlined below.

Table 08: Corrected company model with ERG NMA OS HR

	Δ Cost	Δ QALYs	ICER
Original CS	£163k	2.336	£69,565
Correcting delayed exponential	£161k	2.191	£73,333
Removing lenalidomide PAS	£187k	2.191	£85,557
Applying the ERG NMA OS HR	£169k	-0.382	Dom'ted